Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 1950-1953

  Kerdpin, Oranun ^a,b   Elliot, David J ^a   Mackenzie, Peter I ^a   Miners, John O ^a,c  

^a FLINDERS UNIVERSITY   (Australia)

^b NARESUAN UNIVERSITY   (Thailand)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; GLYCOSYLTRANSFERASE; RECOMBINANT ENZYME; SULFINPYRAZONE; SULFINPYRAZONE BETA DEXTRO GLUCURONIDE; UDP GLUCURONOSYLTRANSFERASE 1A10; UDP GLUCURONOSYLTRANSFERASE 1A7;

ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; HILL REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; MASS SPECTROMETRY; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CATALYSIS; CELLS, CULTURED; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MICROSOMES, LIVER; SULFINPYRAZONE; URICOSURIC AGENTS;

EID: 33751506601     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012385     Document Type: Article

References (20)

1. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigation with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503.
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433.
3. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
4. Dieterle W, Faigle JW, and Moppert J (1980) New metabolites of sulfinpyrazone in man. Arzneim-Forsch 30:989-993.
5. Dieterle W, Faigle JW, Mory H, Richter WJ, and Theobald W (1975) Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man. Eur J Clin Pharmacol 9:135-145.
6. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
7. Margulies EH, White AM, and Sherry S (1980) Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. Drugs 20:179-197.
8. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
9. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
10. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
11. Pittman JR and Bross MH (1999) Diagnosis and management of gout. Am Fam Physician 59:1799-1806.
12. Richter WJ, Alt KO, Dieterle W, Faigle JW, Kriemler HP, Mory H, and Winkler T (1975) C-glucuronides, a novel type of drug metabolites. Helv Chim Acta 58:2512-2517.
13. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062.
14. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
15. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
16. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
17. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
18. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
19. Yamaguchi H, Kubo J, Sekine K, Naruchi T, Hashimoto Y, and Kato R (1979) Metabolites of feprazone in man. Drug Metab Dispos 7:340-344.
20. Yasuda Y, Shindo T, Mitani N, Ishida N, Oono F, and Kageyama T (1982) Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans. J Pharm Sci 71:565-572.